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OBJECTIVE — To investigate whether dietary phylloquinone and menaquinones intakes are
related to risk of type 2 diabetes.
RESEARCH DESIGN AND METHODS — We used data from a prospective cohort
study in 38,094 Dutch men and women, aged 20–70 years. Dietary phylloquinone and mena-
quinones intakes were assessed using a validated food frequency questionnaire. Diabetes case
patients were ascertained mainly via self-report and veriﬁed against medical records.
RESULTS — During 10.3 years of follow-up, 918 incident cases of diabetes were docu-
mented. In a multivariate model adjusting for diabetes risk factors and dietary factors, phyllo-
quinone intake tended to be associated (P  0.08) with a reduced risk of type 2 diabetes with a
hazard ratio (HR) of 0.81 (95% CI 0.66–0.99) for the highest versus the lowest quartile. For
menaquinones intake, a linear, inverse association (P  0.038) with risk of type 2 diabetes was
observed with an HR of 0.93 (0.87–1.00) for each 10-g increment in the multivariate model.
CONCLUSIONS — This study shows that both phylloquinone and menaquinones intakes
may be associated with a reduced risk of type 2 diabetes.
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V
itamin K is a fat-soluble vitamin oc-
curring in two biologically active
forms; vitamin K1 (phylloquinone)
and vitamin K2 (menaquinones). Phyllo-
quinone, the most common form, is
present in green, leafy vegetables and cer-
tain vegetable oils (1), whereas menaqui-
nones occur in animal products such as
meat, eggs, and cheese (2). However,
strong regional differences in the amount
and forms of menaquinones intake exist
(2). Vitamin K functions as a cofactor in
the -carboxylation of certain glutamic
acid (Gla) residues of vitamin K-
dependent proteins for their activation
(3). Vitamin K was known mainly as a
cofactor to carboxylate clotting factors
suchasprothrombin(3).Morerecently,it
became apparent that vitamin K also
carboxylatesotherproteinssuchasosteo-
calcin, a regulator of bone mineral matu-
ration (3).
A recent study showed that osteocal-
cin concentrations may also affect insulin
sensitivity and type 2 diabetes by regulat-
ing the expression of insulin genes and
-cell proliferation markers (4). In mice,
osteocalcin was shown to increase insulin
secretion and insulin sensitivity and de-
crease the severity of type 2 diabetes (4).
This animal study suggested a speciﬁc
rolefortheuncarboxylatedformofosteo-
calcin(4),contradictingaroleforvitamin
K. Subsequent human studies, however,
observed relations between high total or
carboxylated osteocalcin and improved
insulinsensitivity(5,6).Theselatterstud-
ies suggest that vitamin K could reduce
insulin resistance and risk of type 2 dia-
betes by carboxylating osteocalcin.
To date, no studies have investigated
therelationbetweenvitaminKintakeand
riskoftype2diabetesandonlyafewhave
exploredrelationswithinsulinsensitivity.
In rats, vitamin K deﬁciency delayed the
insulin response and decreased plasma
glucose (7). Similar results have been
shown in small-scale human studies
among young men with a low risk of dia-
betes (8). Recently, two larger studies in-
vestigated the relation between dietary
phylloquinone and insulin sensitivity. An
observational study showed that high
phylloquinoneintakewasassociatedwith
improvedinsulinsensitivityandglycemic
control(9).Arandomizedcontrolledtrial
showed improved insulin sensitivity after
phylloquinone supplementation among
men (10). Whether dietary phylloqui-
none or menaquinones intakes are asso-
ciated with a reduced risk of type 2
diabetes is unknown. Therefore, we in-
vestigatedwhetherdietaryphylloquinone
and menaquinones intakes are inversely
associated with type 2 diabetes in a pro-
spective cohort of Dutch men and
women. Because previous studies sug-
gested relations between vitamin K and
inﬂammatory factors or blood lipid pro-
ﬁle (11–14), we explored relations be-
tween phylloquinone and menaquinones
intakes and high-sensitivity C-reactive
protein (CRP), blood lipid proﬁle, and
A1C as a marker of diabetes risk.
RESEARCH DESIGN AND
METHODS— The European Pro-
spective Investigation into Cancer and
Nutrition (EPIC)-NL consists of the two
Dutch contributions to the EPIC study,
the Prospect-EPIC and MORGEN-EPIC
cohorts. These cohorts were set up simul-
taneously in 1993–1997 and merged into
one Dutch EPIC cohort. The design and
rationale of EPIC-NL are described else-
where (15). The Prospect-EPIC study in-
cludes 17,357 women aged 49–70 years
living in Utrecht and vicinity. The MOR-
GEN-EPIC cohort consists of 22,654
adults aged 21–64 years selected from
random samples of the Dutch population
in three Dutch towns. All participants
provided informed consent before study
inclusion. The study complies with the
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pect) and the Medical Ethical Committee
of TNO Nutrition and Food Research
(MORGEN). After exclusion of individu-
als with prevalent diabetes (n  615), in-
dividuals with abnormal energy intake
(kcal600or5,000;n108),missing
nutritional data (n  213), and missing
follow-up (n  981), 38,094 participants
were left for analysis.
Intakes of phylloquinone,
menaquinones, and other nutrients
Daily nutritional intake was obtained
from a food frequency questionnaire
(FFQ) containing questions on the usual
frequency of consumption of 79 main
food items during the year preceding en-
rollment. This questionnaire allows the
estimation of the mean daily consump-
tion of 178 foods. The FFQ has been val-
idated against 12 24-h dietary recalls
(16). The 1996 Dutch food consumption
tablewasusedtocalculateenergyandnu-
trient intakes. This table does not contain
information on vitamin K content of
foods. Therefore, the concentrations of
phylloquinone and menaquinones
(menaquinones subtypes, menaquinones-
4 [MK4] through menaquinones-10
[MK10]) in a series of Dutch foods were
assessed at the Biochemistry Laboratory,
Maastricht University (2). For some
foods,publisheddatabyotherswereused
to update the dietary database for vitamin
K (2,17–19). In total, vitamin K contents
of260foodswerecollectedandtabulated
to estimate phylloquinone and menaqui-
nonesintakes.Weuseddatafromourval-
idation study to determine reliability of
the FFQ to estimate vitamin K intake
against 12 24-h recalls in 58 women and
63 men (16). We observed a low relative
validity of phylloquinone and MK10 in-
takes with correlations of the FFQ against
24-h recalls of 0.24 and 0.23, respec-
tively. Relative validity for intakes of
menaquinones and MK4 to MK9 was rea-
sonable to good with correlation ranging
from 0.51 for MK7 to 0.73 for MK5. In-
takes of nutrients were adjusted for en-
ergy intake by the regression residual
method.
Diabetes
Occurrence of diabetes during follow-up
was self-reported in two follow-up ques-
tionnaires with 3- to 5-year intervals. Par-
ticipants were asked whether diabetes
was diagnosed, in what year, and by
whom and what treatment was received.
In the Prospect study, incident cases of
diabetes were detected via a urinary glu-
cose strip test, sent out with the ﬁrst fol-
low-up questionnaire, for detection of
glucosuria. Diagnoses of diabetes were
also obtained from the Dutch Centre for
Health Care Information, which holds a
standardized computerized register of
hospital discharge diagnoses. In this reg-
ister, admission ﬁles have been entered
continuously from all general and univer-
sity hospitals in the Netherlands from
1990 onward. All diagnoses were coded
according to the ICD-9-CM. Follow-up
was complete on 1 January 2006. Poten-
tial cases identiﬁed by any of these meth-
ods were veriﬁed against participants’
general practitioner or pharmacist infor-
mation through mailed questionnaires.
Diabetes was deﬁned as being present
when either of these conﬁrmed the diag-
nosis. For 89% of participants with po-
tential diabetes, veriﬁcation information
was available, and 72% were veriﬁed as
having type 2 diabetes and were used for
the analysis.
Other measurements
At baseline, participants ﬁlled out a gen-
eral questionnaire containing questions
on demographics, presence of chronic
diseases, and risk factors for chronic dis-
eases. Smoking was categorized into cur-
rent, past, and never smoker and parental
history of diabetes into none, one, or two
parents.Systolicanddiastolicbloodpres-
suremeasurementswereperformedtwice
on the right arm with the participant in
the supine position using a Boso Oscil-
lomat (Bosch & Son, Jungingen, Ger-
many) (Prospect) or on the left arm
using a random zero sphygmomanome-
ter (MORGEN), andthemeanwastaken.
Hypertension was deﬁned as being
present based on diastolic blood pressure
90 mmHg, systolic blood pressure
140mmHg,self-reporteduseofantihy-
pertensive medication, or self-reported
presence of hypertension. Physical activ-
itywasassessedusingaquestionnaireval-
idated in an elderly population, and the
Cambridge Physical Activity Score was
calculatedandusedtocategorizephysical
activity (20). Because we could not calcu-
late a total physical activity score for 14%
of all participants, we imputed missing
scoresbymeansofsinglelinearregression
modeling (SPSS MVA procedure). Waist
circumference, height, and weight were
measuredandBMIwascalculated(weight
in kilograms divided by the square of
heightinmeters).A6.5%randomsample
(n  2,604) of the baseline cohort was
drawn for more detailed biochemical
measurements. The baseline characteris-
tics of this random sample were similar to
the baseline characteristics of the entire
cohort (15). Thus, the random sample is
representative of the full baseline cohort
and can therefore be used to explore
relations between risk markers and other
exposures.A1Cwasmeasuredinerythro-
cytesusinganimmunoturbidimetriclatex
test, total cholesterol and triglycerides
weremeasuredusingenzymaticmethods,
high-sensitivityCRPwasmeasuredwitha
turbidimetric method, and HDL choles-
terol and LDL cholesterol were measured
using a homogeneous assay with an enzy-
matic end point (15).
Data analysis
Baseline characteristics by quartiles of en-
ergy-adjusted dietary phylloquinone and
menaquinoneswereinspectedusinganal-
ysis of variance for continuous variables
and a 
2 test for categorical variables. We
calculated person-years of follow-up for
eachparticipantfromthedateofreturnof
the questionnaire to the date of type 2
diabetes, the date of death, or 1 January
2006.WeusedCoxregressiontoestimate
hazard ratios (HRs) for type 2 diabetes for
quartiles of either energy-adjusted phyl-
loquinone or menaquinones intake and
for each 50-g increment of energy-
adjusted phylloquinone intake and for
each 10-g increment of energy-adjusted
menaquinones intake. These increments
were based on an approximately half SD
for phylloquinone (SD 98) and menaqui-
nones (SD 17). We adjusted for type 2
diabetes risk factors and dietary factors
using three models. The ﬁrst model was
adjusted for age, sex, and waist circum-
ference. In a second model, we included
smoking status (non/current/former),
physical activity (four categories), educa-
tion (three categories), hypertension, al-
cohol consumption, and total energy
intake (both continuous). In the ﬁnal
multivariate model, we also adjusted for
diet by including energy-adjusted intake
ofsaturated,polyunsaturated,andmono-
unsaturated fat, protein, ﬁber, calcium,
vitaminC,andvitaminEinthemodel(all
continuous). We checked whether inter-
action of sex, waist circumference, and
BMIwithphylloquinoneandmenaquino-
nes intakes was present by including the
interaction terms in the model. The pres-
ence of a nonlinear association of phyllo-
quinone or menaquinones intake was
explored by including the quadratic term
of phylloquinone and menaquinones in
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sibility of a nonlinear relation was further
examined nonparametrically with re-
strictedcubicsplines(21).Thelikelihood
ratio text was used for nonlinearity, com-
paring the model with only the linear
term to the model with the linear and cu-
bic spline terms. Associations between
risk markers and phylloquinone and
menaquinones intakes (both modeled
continuously per 50 and 10 g) were as-
sessed by linear regression using the third
multivariate model in the baseline ran-
dom sample. In these analyses, we ex-
cluded those with CRP 10 mg/l
(indicating active infection; n  72) and
A1C 6.5% (indicating the presence of
diabetes; n  60). Data analysis was per-
formed using SPSS (version 15.0 for
Windows) and SAS (version 9.1 for
Windows).
RESULTS— Intake of phylloquinone
was20098g/dayandintakeofmena-
quinones was 31  7 g/day in our study
population. Vegetables contributed 78%
of phylloquinone intake, whereas cheese
contributed 53%, milk products 19%,
and meat 17% of menaquinones intake.
Age- and energy-adjusted intake of pro-
tein was higher with higher phylloqui-
noneandmenaquinonesintakes,whereas
percent men and prevalence of physical
inactivity were lower with higher intakes
ofphylloquinoneandmenaquinones(Ta-
ble1).Withhigherphylloquinoneintake,
we observed higher intakes of energy-
adjusted ﬁber and vitamin C, whereas al-
cohol consumption was lower. Alcohol
consumption and energy-adjusted intake
of saturated fat and calcium were higher
with higher menaquinones intake and
prevalence of smoking was lower with
higher menaquinone intake (Table 1).
During a median follow-up of 10.3
years, we documented 918 veriﬁed cases
of type 2 diabetes. In an age-, sex-, and
waist-adjusted model, phylloquinone in-
takewasnotassociatedwithriskoftype2
diabetes with an HR of 1.00 (95% CI
0.97–1.03) for each 50-g increment
(Table 2). However, with adjustment for
diabetes risk factors and dietary factors,
quartiles of phylloquinone intake tended
tobeassociated(P0.08)withareduced
risk of type 2 diabetes with an HR of 0.81
(0.66–0.99) for the highest versus the
lowest quartile. This association, how-
ever,remainednonsigniﬁcantwhenmod-
eled linearly per 50 g. This result was
duetothepresenceofanonlinearrelation
as indicated by a signiﬁcant quadratic
term (P  0.016). Spline regression in-
deed showed evidence of a nonlinear
relation (P  0.053) between phylloqui-
none intake and type 2 diabetes with a
linear risk reduction at lower levels,
reaching a plateau at higher levels of in-
take with an HR of 	0.65 (Fig. 1).
Menaquinonesintaketendedtobein-
verselyassociated(P0.060)withriskof
type 2 diabetes with an HR of 0.95 (95%
CI 0.91–1.01) for each 10-g increment
in an age-, sex-, and waist-adjusted
model. In the ﬁnal multivariate model, an
inverse association (P  0.038) was ob-
servedwithanHRof0.93(0.87–1.00)for
each 10-g increment of menaquinones
intake. These results were similar using
quartiles of menaquinones intake. Spline
regression showed a linear inverse associ-
ation(P0.035)betweenmenaquinones
intake and type 2 diabetes without evi-
dence for a nonlinear relation.
The interaction between sex and
phylloquinone or menaquinones intakes
was not signiﬁcant, nor was the interac-
tion with waist circumference or BMI. If
waist circumference was replaced with
BMIinthemodel,similarresultswereob-
served for menaquinones (HR 0.93 [95%
CI 0.86–0.99]) and phylloquinone (0.98
[0.95–1.02]). Adjustment for parental
history of type 2 diabetes did not change
the results for phylloquinone (0.99
[0.95–1.02]) or menaquinones (0.94
[0.87–1.00]) intake nor did adjustment
for vitamin D intake (menaquinones:
0.93 [0.87–1.00]; phylloquinone: 0.98
[0.95–1.02]).
In the baseline random sample (n 
1,604), used for the hypothesis-
generating analysis, HDL cholesterol
tendedtobehigherwithhighermenaqui-
nones intake (ß 0.01  0.007; P  0.11).
The HDL cholesterol-to-total cholesterol
ratio was higher with higher menaquino-
nes intake (ß 0.003  0.001; P  0.034).
High-sensitivity CRP was inversely asso-
ciated with menaquinones intake (ß

0.10  0.04; P  0.016). None of the
other risk markers (A1C, total choles-
terol, LDL cholesterol, or triglycerides)
were associated with menaquinones in-
take. Phylloquinone intake was not asso-
ciated with any of the risk markers (data
not shown).
CONCLUSIONS— In this large co-
hort of 38,094 Dutch men and women,
both dietary phylloquinone and mena-
quinones intakes were associated with a
reducedriskoftype2diabetes.Thisasso-
ciation was linear inverse for menaquino-
nes, whereas a signiﬁcant risk reduction
for phylloquinone was observed at higher
intakes, in particular. High dietary mena-
quinones intake was associated with
lower CRP concentrations and an im-
proved blood lipid proﬁle.
The strengths of this study include its
prospective design, long follow-up, large
sample size, and veriﬁcation of type 2 di-
abetes against medical records. However,
certain limitations need to be addressed.
The main limitation was the determina-
tion of dietary intakes of phylloquinone
and menaquinones using an FFQ. Al-
though the FFQ was not validated for
phylloquinone and menaquinones at that
time, we estimated relative validity of
phylloquinone and menaquinones using
the data of the validation study. Relative
validity of our FFQ for phylloquinone in-
take was low, but for menaquinones in-
take it was reasonable with correlation
coefﬁcients well in line with those of
many other nutrients estimated using
FFQs (16). In addition, FFQs are valid
toolstorankparticipantsaccordingtonu-
tritional intake but are not designed to
estimate absolute intakes. Therefore, we
canonlyuseourdatatoshowtheshapeof
associations, but exact amounts for a
threshold cannot be determined.
Second,asinanyobservationalstudy,
our results could be inﬂuenced in part by
differencesinfactorsotherthanvitaminK
intake. Phylloquinone and menaquino-
nes intakes are associated with different,
almost opposite, lifestyle behaviors.
Vegetable intake contributes mostly to
phylloquinone intake and is associated
with a healthy lifestyle. Residual con-
founding in this case could therefore lead
to an inverse association between phyllo-
quinone intake and type 2 diabetes. In
contrast, consumption of meat, milk
products, and cheese contributes to
menaquinones intake and is related to an
unhealthier lifestyle and higher risk of
type 2 diabetes. Residual confounding in
this case would therefore attenuate our
results for menaquinones intake. Al-
though we simultaneously adjusted for
several diabetes risk factors and these di-
etary factors in our analysis, residual con-
founding may be present.
Finally, relations between phylloqui-
none and menaquinones intakes and risk
markers were explored cross-sectionally
in a baseline random sample. These re-
sults should therefore be regarded as hy-
pothesis-generating to explain the
relation with type 2 diabetes and not as a
causal relation.
Beulens and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 8, AUGUST 2010 1701T
a
b
l
e
1
—
B
a
s
e
l
i
n
e
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
a
c
c
o
r
d
i
n
g
t
o
q
u
a
r
t
i
l
e
s
o
f
e
n
e
r
g
y
-
a
d
j
u
s
t
e
d
p
h
y
l
l
o
q
u
i
n
o
n
e
a
n
d
m
e
n
a
q
u
i
n
o
n
e
s
i
n
t
a
k
e
o
f
3
8
,
0
9
4
D
u
t
c
h
a
d
u
l
t
s
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
P
h
y
l
l
o
q
u
i
n
o
n
e
M
e
n
a
q
u
i
n
o
n
e
s
Q
u
a
r
t
i
l
e
1
(
l
o
w
)
Q
u
a
r
t
i
l
e
2
Q
u
a
r
t
i
l
e
3
Q
u
a
r
t
i
l
e
4
(
h
i
g
h
)
Q
u
a
r
t
i
l
e
1
(
l
o
w
)
Q
u
a
r
t
i
l
e
2
Q
u
a
r
t
i
l
e
3
Q
u
a
r
t
i
l
e
4
(
h
i
g
h
)
n
9
,
5
2
3
9
,
5
2
4
9
,
5
2
4
9
,
5
2
3
9
,
4
8
6
9
,
5
5
7
9
,
5
5
7
9
,
4
9
4
P
h
y
l
l
o
q
u
i
n
o
n
e
(

g
)
9
5
.
7

2
4
.
6
1
5
5
.
8

1
5
.
1
2
1
3
.
1

1
9
.
1
3
3
2
.
9

8
2
.
5
1
8
7
.
1

9
7
.
3
2
0
0
.
6

9
6
.
8
2
0
5
.
3

9
9
.
5
2
0
4
.
5

9
8
.
6
M
e
n
a
q
u
i
n
o
n
e
s
(

g
)
2
9
.
4

1
4
.
5
3
0
.
3

1
3
.
6
3
0
.
9

1
3
.
3
3
1
.
5

1
3
.
5
1
5
.
4

3
.
7
2
4
.
5

2
.
2
3
3
.
0

2
.
8
4
9
.
1

1
0
.
8
M
a
l
e
s
e
x
3
,
2
0
4
(
3
3
.
6
)
2
,
7
3
8
(
2
8
.
7
)
2
,
1
9
1
(
2
3
.
0
)
1
,
6
0
7
(
1
6
.
9
)
3
,
5
0
9
(
3
7
.
0
)
2
,
5
8
5
(
2
7
.
0
)
2
,
0
3
3
(
2
1
.
3
)
1
,
6
1
3
(
1
7
.
0
)
A
g
e
(
y
e
a
r
s
)
4
6
.
3

1
2
.
4
4
8
.
2

1
1
.
8
4
9
.
8

1
1
.
6
5
2
.
2

1
0
.
9
4
4
.
9

1
2
.
9
4
9
.
0

1
1
.
9
5
0
.
5

1
1
.
2
5
2
.
0

1
0
.
2
B
M
I
(
k
g
/
m
2
)
2
5
.
3

3
.
9
2
5
.
4

3
.
9
2
5
.
6

3
.
9
2
6
.
1

4
.
2
2
5
.
3

3
.
9
2
5
.
7

4
.
0
2
5
.
8

4
.
0
2
5
.
8

4
.
1
W
a
i
s
t
c
i
r
c
u
m
f
e
r
e
n
c
e
(
c
m
)
8
4
.
7

1
1
.
7
8
4
.
8

1
1
.
4
8
5
.
0

1
1
.
2
8
5
.
7

1
1
.
3
8
4
.
9

1
1
.
7
8
5
.
4

1
1
.
4
8
5
.
2

1
1
.
2
8
4
.
8

1
1
.
4
C
u
r
r
e
n
t
s
m
o
k
e
r
3
,
1
6
7
(
3
3
.
3
)
2
,
8
6
0
(
3
0
.
1
)
2
,
7
5
4
(
2
9
.
0
)
2
,
8
4
9
(
3
0
.
0
)
3
,
3
7
6
(
3
5
.
7
)
2
,
9
7
9
(
3
1
.
3
)
2
,
7
0
7
(
2
8
.
4
)
2
,
5
6
8
(
2
7
.
1
)
P
h
y
s
i
c
a
l
l
y
i
n
a
c
t
i
v
e
*
1
,
0
7
9
(
1
1
.
3
)
8
0
8
(
8
.
5
)
7
8
5
(
8
.
2
)
8
2
9
(
8
.
7
)
1
,
1
6
9
(
1
2
.
3
)
8
7
1
(
9
.
1
)
7
5
0
(
7
.
8
)
7
1
1
(
7
.
5
)
H
i
g
h
e
r
e
d
u
c
a
t
i
o
n
2
,
2
5
7
(
2
3
.
7
)
2
,
0
3
0
(
2
1
.
3
)
1
,
9
5
5
(
2
0
.
5
)
1
,
5
8
8
(
1
6
.
7
)
1
,
6
7
6
(
1
7
.
7
)
1
,
7
7
0
(
1
8
.
5
)
2
,
0
2
4
(
2
1
.
2
)
2
,
3
6
0
(
2
4
.
9
)
F
a
m
i
l
y
h
i
s
t
o
r
y
o
f
d
i
a
b
e
t
e
s
1
,
5
7
0
(
1
6
.
5
)
1
,
6
7
4
(
1
7
.
6
)
1
,
7
5
9
(
1
8
.
5
)
1
,
8
6
0
(
1
9
.
5
)
1
,
4
8
2
(
1
5
.
6
)
1
,
7
8
3
(
1
8
.
7
)
1
,
8
5
1
(
1
9
.
4
)
1
,
7
4
7
(
1
8
.
4
)
S
y
s
t
o
l
i
c
b
l
o
o
d
p
r
e
s
s
u
r
e
(
m
m
H
g
)
1
2
4
.
3

1
8
.
5
1
2
5
.
1

1
8
.
1
1
2
6
.
7

1
9
.
0
1
2
8
.
1

1
9
.
5
1
2
3
.
6

1
8
.
0
1
2
6
.
1

1
8
.
6
1
2
7
.
0

1
9
.
1
1
2
7
.
3

1
9
.
3
D
i
a
s
t
o
l
i
c
b
l
o
o
d
p
r
e
s
s
u
r
e
(
m
m
H
g
)
7
7
.
4

1
0
.
8
7
7
.
6

1
0
.
4
7
7
.
9

1
0
.
6
7
8
.
2

1
0
.
7
7
7
.
1

1
0
.
4
7
7
.
9

1
0
.
7
7
8
.
0

1
0
.
7
7
8
.
0

1
0
.
7
H
y
p
e
r
t
e
n
s
i
o
n
3
,
2
2
5
(
3
3
.
9
)
3
,
3
0
7
(
3
4
.
7
)
3
,
6
0
5
(
3
7
.
9
)
3
,
9
0
8
(
4
1
.
0
)
3
,
0
9
6
(
3
2
.
6
)
3
,
5
9
2
(
3
7
.
6
)
3
,
6
6
4
(
3
8
.
3
)
3
,
6
9
3
(
3
8
.
9
)
H
y
p
e
r
l
i
p
i
d
e
m
i
a
7
7
1
(
8
.
1
)
7
8
7
(
8
.
3
)
7
4
8
(
7
.
9
)
8
2
8
(
8
.
7
)
9
5
8
(
1
0
.
1
)
8
3
6
(
8
.
7
)
7
3
8
(
7
.
7
)
6
0
2
(
6
.
3
)
A
l
c
o
h
o
l
i
n
t
a
k
e
(
g
/
d
a
y
)
†
5
.
6
(
1
6
.
7
)
5
.
7
(
1
5
.
3
)
5
.
2
(
1
4
.
3
)
4
.
1
(
1
3
.
7
)
4
.
3
(
1
5
.
7
)
5
.
2
(
1
5
.
4
)
5
.
2
(
1
4
.
1
)
5
.
7
(
1
4
.
9
)
D
i
e
t
‡
E
n
e
r
g
y
i
n
t
a
k
e
(
k
c
a
l
/
d
a
y
)
2
,
0
6
0

6
4
9
2
,
1
0
3

6
2
4
2
,
0
7
1

6
1
2
1
,
9
8
4

5
9
0
2
,
0
8
7

6
6
9
2
,
0
6
4

6
1
8
2
,
0
4
3

5
9
0
2
,
0
2
4

6
0
1
S
a
t
u
r
a
t
e
d
f
a
t
i
n
t
a
k
e
(
g
/
d
a
y
)
3
1
.
9

5
.
9
3
2
.
5

5
.
8
3
2
.
8

5
.
7
3
3
.
1

6
.
1
2
9
.
4

5
.
4
3
1
.
7

5
.
2
3
3
.
2

5
.
1
3
5
.
9

5
.
8
P
U
F
A
i
n
t
a
k
e
(
g
/
d
a
y
)
1
4
.
5

3
.
9
1
4
.
9

3
.
7
1
5
.
1

3
.
8
1
5
.
3

4
.
1
1
5
.
5

4
.
2
1
5
.
2

3
.
8
1
4
.
9

3
.
7
1
4
.
3

3
.
7
M
U
F
A
i
n
t
a
k
e
(
g
/
d
a
y
)
2
9
.
2

5
.
2
2
9
.
5

5
.
0
2
9
.
6

5
.
1
2
9
.
5

5
.
3
2
9
.
0

5
.
6
2
9
.
4

5
.
1
2
9
.
5

4
.
9
3
0
.
0

5
.
0
P
r
o
t
e
i
n
i
n
t
a
k
e
(
g
/
d
a
y
)
7
3
.
5

1
1
.
3
7
5
.
0

1
0
.
4
7
6
.
2

1
0
.
5
7
8
.
2

1
1
.
2
6
9
.
0

1
0
.
3
7
4
.
1

9
.
4
7
7
.
5

9
.
5
8
2
.
3

1
0
.
2
F
i
b
e
r
i
n
t
a
k
e
(
g
/
d
a
y
)
2
1
.
1

4
.
6
2
2
.
9

4
.
4
2
3
.
9

4
.
4
2
5
.
5

4
.
7
2
3
.
0

5
.
3
2
3
.
4

4
.
8
2
3
.
6

4
.
5
2
3
.
4

4
.
6
V
i
t
a
m
i
n
C
i
n
t
a
k
e
(
m
g
/
d
a
y
)
9
4
.
2

3
9
.
6
1
0
7
.
0

4
2
.
9
1
1
3
.
6

4
4
.
3
1
2
2
.
8

4
9
.
2
1
0
1
.
5

4
7
.
2
1
0
8
.
5

4
4
.
3
1
1
3
.
0

4
3
.
9
1
1
4
.
6

4
4
.
8
V
i
t
a
m
i
n
E
i
n
t
a
k
e
(
m
g
/
d
a
y
)
1
1
.
5

3
.
2
1
2
.
0

3
.
1
1
2
.
4

3
.
1
1
3
.
0

3
.
4
1
2
.
6

3
.
5
1
2
.
4

3
.
3
1
2
.
2

3
.
1
1
1
.
7

3
.
0
C
a
l
c
i
u
m
i
n
t
a
k
e
(
m
g
/
d
a
y
)
1
,
0
0
3

3
7
0
1
,
0
5
0

3
4
7
1
,
0
7
9

3
4
3
1
,
1
3
0

3
4
9
8
0
4

2
9
6
9
9
0

2
8
5
1
,
1
2
7

2
8
3
1
,
3
4
0

3
2
0
D
a
t
a
a
r
e
m
e
a
n
s

S
D
o
r
n
(
%
)
u
n
l
e
s
s
o
t
h
e
r
w
i
s
e
i
n
d
i
c
a
t
e
d
.
P
t
r
e
n
d

0
.
0
0
1
e
x
c
e
p
t
f
o
r
w
a
i
s
t
c
i
r
c
u
m
f
e
r
e
n
c
e
o
v
e
r
m
e
n
a
q
u
i
n
o
n
e
s
c
a
t
e
g
o
r
i
e
s
.
M
U
F
A
,
m
o
n
o
u
n
s
a
t
u
r
a
t
e
d
f
a
t
;
P
U
F
A
,
p
o
l
y
u
n
s
a
t
u
r
a
t
e
d
f
a
t
.
*
I
n
a
c
t
i
v
e
a
c
c
o
r
d
i
n
g
t
o
t
h
e
C
a
m
b
r
i
d
g
e
p
h
y
s
i
c
a
l
a
c
t
i
v
i
t
y
i
n
d
e
x
.
†
M
e
d
i
a
n
(
i
n
t
e
r
q
u
a
r
t
i
l
e
r
a
n
g
e
)
.
‡
A
l
l
n
u
t
r
i
e
n
t
s
a
r
e
e
n
e
r
g
y
a
d
j
u
s
t
e
d
e
x
c
e
p
t
e
n
e
r
g
y
i
n
t
a
k
e
.
Phylloquinone, menaquinones, and type 2 diabetes
1702 DIABETES CARE, VOLUME 33, NUMBER 8, AUGUST 2010 care.diabetesjournals.orgTo the best of our knowledge, this is
the ﬁrst study to investigate the relation
between vitamin K intake and risk of type
2 diabetes. Two previous studies have in-
vestigated the relation between phyllo-
quinone intake and insulin sensitivity or
glycemicmarkers.Anobservationalstudy
showed an inverse relation of phylloqui-
none intake with 2-h glucose concentra-
tions and insulin sensitivity among 2,719
women (9). A subsequent trial among
nondiabetic men and women showed re-
ducedprogressionofinsulinresistanceaf-
ter 3 years of supplementation with 500
g daily among men only (10). In this
large population of Dutch men and
women, phylloquinone intake was asso-
ciated with a reduced risk of type 2 dia-
betesparticularlyathigherintakes,inline
withthesepreviousstudies.Formenaqui-
nones intake, we observed a linear, in-
verse association with type 2 diabetes. No
previous studies have studied the relation
of menaquinones intake with insulin sen-
sitivity or markers of glycemic status. The
differentshapeoftheassociationsofphyl-
loquinoneandmenaquinonesmaybedue
to the lower ranges of intake of menaqui-
nones compared with that of phylloqui-
none. Sensitivity of FFQs to differentiate
at higher levels of intake may also be in-
volved, because a plateau effect in the re-
lation between plasma phylloquinone
and phylloquinone intake from an FFQ
has been reported previously (22).
On the other hand, the differences
may also be explained by differences in
distribution and metabolism of both
forms. Because phylloquinone is trans-
ported with the triacylglycerol-rich frac-
tion and menaquinones are transported
both by triacylglycerol-rich lipoprotein
and LDL, phylloquinone is more effec-
tively cleared from the circulation by the
liver for activation of clotting factors than
Figure 1—Association between phylloquinone intake and risk of type 2 diabetes modeled contin-
uously using splines; HR (——) with 95% CI in gray.
Table 2—Energy-adjusted phylloquinone and menaquinones intake and risk of type 2 diabetes among 38.094 Dutch men and women
Quartile 1 Quartile 2 Quartile 3 Quartile 4 Ptrend value Per 50 g
Phylloquinone
Intake (g/day) 100.1 155.7 211.4 308.1
Age-, sex-, waist-adjusted 1.0 0.89 (0.73–1.08) 0.95 (0.79–1.14) 0.89 (0.74–1.07) 0.35 1.00 (0.97–1.03) P  0.92
Multivariate adjusted* 1.0 0.89 (0.74–1.09) 0.94 (0.78–1.14) 0.88 (0.73–1.06) 0.26 0.99 (0.96–1.02) P  0.65
Multivariate adjusted† 1.0 0.87 (0.71–1.06) 0.90 (0.74–1.09) 0.81 (0.66–0.99) 0.08 0.98 (0.95–1.02) P  0.31
Menaquinones
Intake (g/day) 16.0 24.5 32.9 46.1 Per 10 g
Age-, sex-, waist-adjusted 1.0 1.03 (0.85–1.25) 0.95 (0.78–1.15) 0.86 (0.71–1.05) 0.07 0.95 (0.91–1.01) P  0.060
Multivariate adjusted* 1.0 1.04 (0.86–1.26) 0.97 (0.80–1.17) 0.88 (0.73–1.08) 0.13 0.96 (0.91–1.02) P  0.12
Multivariate adjusted† 1.0 0.99 (0.82–1.21) 0.89 (0.72–1.10) 0.80 (0.62–1.02) 0.04 0.93 (0.87–1.00) P  0.038
Data are HRs (95% CI). *Adjusted for age, sex, waist circumference, smoking status, physical activity, hypertension, education, alcohol consumption, and total
energy intake. †Adjusted for confounders in footnote * and energy-adjusted intake of saturated, polyunsaturated, and monounsaturated fat, protein, ﬁber, calcium,
vitamin C, and vitamin E.
Beulens and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 8, AUGUST 2010 1703menaquinones (23). An intervention
study indeed suggested that MK7 more
effectively carboxylated osteocalcin than
phylloquinone (24). However, because
both forms have the same function in car-
boxylation of proteins, both should have
similar effects that could only differ in
dosage. More research is, however,
needed to assess whether differences are
indeedpresentbetweenbothformsandat
what dosage.
Theunderlyingmechanismforthere-
lation between vitamin K intake and type
2 diabetes is unknown, but several path-
ways may be involved. First, vitamin K
could inﬂuence insulin sensitivity and
risk of type 2 diabetes by carboxylating
osteocalcin. Osteocalcin was suggested to
function as a hormone in energy metabo-
lism, regulating insulin sensitivity
through an effect on adiponectin (4).
However, only the uncarboxylated form
seems to function hormonally in energy
metabolism (4), making it unlikely to ex-
plain effects through carboxylation by vi-
tamin K.
Osteocalcin also functions as a regu-
latorofbonemineralmaturationbybind-
ing calcium (3). Because both calcium
and vitamin D insufﬁciency are consis-
tently associated with an increased risk of
type 2 diabetes (25), vitamin K could re-
duce insulin resistance and risk of type 2
diabetes through effects on calcium me-
tabolism. However, adjustment for cal-
cium intake and vitamin D in our study
did not affect the associations. Finally,
preliminary studies have shown that vita-
min K inﬂuences other diabetes risk fac-
tors. Both in vitro (13) and observational
(14)studiesshowedthatvitaminKintake
may decrease inﬂammation, which could
also improve insulin sensitivity. Previous
studies showed that menaquinones sup-
plementation improved the blood lipid
proﬁle (12), whereas phylloquinone sup-
plementation increased triglyceride and
decreased HDL cholesterol concentra-
tions after 6 weeks (11). These studies are
conﬁrmedbyourexploratoryresultswith
risk markers and could explain the in-
verse relation between dietary menaqui-
nones and type 2 diabetes.
Insummary,theﬁndingsofthisstudy
showthatbothphylloquinoneandmena-
quinonesintakesmaybeassociatedwitha
reduced risk of type 2 diabetes. For phyl-
loquinone intake, these risk reductions
occurred at higher levels of intake,
whereas for menaquinones a linear in-
verse association was observed.
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